-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

625.O1.6 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Leukemia, Biological, apoptosis, antibodies, Adult, Follicular Lymphoma, multiple myeloma, CLL, bioengineering, Diseases, Lymphoma (any), drug-drug interaction, Marginal Zone Lymphoma, Combinations, Therapies, CAR-Ts, Mantle Cell Lymphoma, cell regulation, checkpoint inhibitors, Non-Hodgkin Lymphoma, white blood cells, Biological Processes, enzyme inhibitors, DLBCL, B-Cell Lymphoma, T-Cell Lymphoma, Technology and Procedures, gene therapy, immune cells, immunotherapy, Cell Lineage, Plasma Cell Disorders, Xenograft models, Lymphoid Malignancies, gene editing, Study Population, Clinically relevant, genomics, immune mechanism, flow cytometry, NGS, microenvironment, RNA sequencing, molecular interactions, pathogenesis, pathways, proteomics, signal transduction
Saturday, December 5, 2020: 12:00 PM-1:30 PM
Moderators:
Marco Ruella, MD, University of Pennsylvania and Daniel J. Hodson, MD, PhD, University of Cambridge
Disclosures:
Hodson: Gilead Sciences: Research Funding.
12:00 PM
171
Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage RepairClinically Relevant Abstract

Jithma P. Abeykoon, MD1,2, Xiaosheng Wu, MD1*, Kevin E. Nowakowski1*, Surendra Dasari, PhD3*, Jonas Paludo, MD1, S. John Weroha2*, Chunling Hu, PhD2*, Jann Sarkaria2*, Ann Mladek2*, Jessica Phillips, PhD2*, Andrew L. Feldman, MD4, Aishwarya Ravindran, MBBS5, Rebecca L. King, MD4, Mary J. Stenson1*, Michelle Manske, MS, BS1*, Fergus Couch2*, Mrinal M. Patnaik, MD, MBBS1 and Thomas E. Witzig, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Mayo Clinic, Rochester, MN
3Department of Health Sciences Research, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
5Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
12:15 PM
172
Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell LymphomaClinically Relevant Abstract

Vivian Changying Jiang, PhD1, Junwei Lian, PhD1*, Shengjian Huang, PhD1*, Shaojun Zhang, PhD2*, Yang Liu, PhD1*, Linghua Wang, MD, PhD, MS2 and Michael Wang, MD1,3

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
12:30 PM
173
DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Ewa Cendrowicz, PhD1*, Lisa Jacob2*, Shirley Greenwald3*, Ami Tamir2*, Yosi Gozlan2*, Gerwin Huls, MD, PhD4*, Adam Foley-Comer2*, Yaron Pereg2*, Ayelet Chajut2*, Amnon Peled, Ph.D.5* and Edwin Bremer, PhD4*

1Department of Hematology, Unlverslty Medlcal Center Groningen, Groningen, Netherlands
2Kahr MedicalLtd., Jerusalem, Israel
3Kahr Medical Ltd., Jerusalem, Israel
4Hematology, University Medical Center Groningen, Groningen, Netherlands
5Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel
12:45 PM
174
In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model

Adam Yuh Lin, MD, PhD1, Bongseo Choi, PhD2*, Taehoon Sim, PhD2*, Leo I. Gordon, MD3 and Dong-Hyun Kim, PhD2*

1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
2Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL
3Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
1:00 PM
175
Paired Single Cell RNA and TCR Sequencing Analysis Following PD-L1 Blockade in Cutaneous T-Cell LymphomaClinically Relevant Abstract

Christiane Querfeld, MD, PhD1, Xiwei Wu, PhD2*, Hanjun Qin, PhD3*, Chingyu Su4*, Zhen Han5* and Steven T. Rosen, MD1,6

1Beckman Research Institute, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
2Beckman Research Institute; Integrative Genomics Core, City of Hope, Duarte, CA
3Department of Integrative Genomics Core, Beckman Research Institute, City of Hope, Duarte, CA
4Beckman Research Institute, City of Hope, Duarte, CA
5Division of Dermatology, Beckman Research Institute, City of Hope, Duarte, CA
6Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA
1:15 PM
176
Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHLClinically Relevant Abstract

Jie Zhang, PhD* and Zhenhao Zhou, MD*

Chimagen Biosciences, Shanghai, China
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH